Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 11 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

9%

1 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

11Total
Not Applicable (5)
P 1 (5)
P 4 (1)

Trial Status

Completed6
Not Yet Recruiting3
Recruiting2

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 6 completed trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07562256Not ApplicableCompleted

Effects of Different Doses of Caffeine on Physical and Cognitive Performance in Female Handball Players

NCT07514013Not ApplicableRecruiting

Examining Olive Oil Extract on Knee Comfort and Function

NCT07511439Phase 4Not Yet Recruiting

Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission

NCT07232121Phase 1Recruiting

A Study to Evaluate the Safety of Increasing Doses of DF5112 in Healthy Adults

NCT07459465Not ApplicableNot Yet RecruitingPrimary

Postprandial Triglyceride Concentrations Across Menstrual Cycle Phases

NCT07405957Not ApplicableCompletedPrimary

Effects of Two Different Lion's Mane Extracts (Lions Mane Fruiting Body & Lions Mane Fruiting Body With Mycellium) on Cognitive Performance, Subjective Affect, Serum Biomarkers, and Gut Microbiota in Healthy Adults

NCT07069621Not ApplicableCompleted

Triple P forADHD Children's Mothers, Education of Behavioral Problems, and Change in Mothers' Attitude

NCT07366931Phase 1Not Yet RecruitingPrimary

The Effect of Daily Supplementation With Humiome® Post LB on Gastrointestinal Symptoms in Female Athletes

NCT02039323Phase 1CompletedPrimary

A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants

NCT01330199Phase 1CompletedPrimary

Pharmacokinetics of Tenofovir, Emtricitabine, Maraviroc, and Raltegravir in Cervical, Vaginal, and Rectal Tissues and Secretions

NCT01404806Phase 1CompletedPrimary

GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue in Healthy Female Subjects

Showing all 11 trials

Research Network

Activity Timeline